ESMO 2016 Immunotherapy for GU cancers: latest advances and future approaches
The rapidly evolving field of immunotherapy in the treatment of genitourinary (GU) cancers was covered in a satellite symposium, sponsored by F. Hoffmann-La Roche, and held at the European Society for Medical Oncology (ESMO) congress, in Copenhagen on 9 October 2016. Chaired by Dr Elizabeth Pilmack, Philadelphia, PA, USA, Drs Ignacio Duran, Bernard Escudier and Aurelien Marabelle discussed the rationale for immunotherapy in GU cancers, current options for urothelial cancer, and the future of immunotherapy for renal cell carcinoma.
Recent developments with immunotherapy in bladder cancer: an interactive case study session
Using clinical case studies, Professor Thomas Powles discusses the management of patients with urothelial cancer treated with checkpoint inhibitors.
Support: The satellite symposium and accompanying video content was supported by Roche.